PMID- 20864639
OWN - NLM
STAT- MEDLINE
DCOM- 20110228
LR  - 20221207
IS  - 1943-7811 (Electronic)
IS  - 1525-1578 (Print)
IS  - 1525-1578 (Linking)
VI  - 12
IP  - 6
DP  - 2010 Nov
TI  - Detection of TERC amplification in cervical epithelial cells for the diagnosis of 
      high-grade cervical lesions and invasive cancer: a multicenter study in China.
PG  - 808-17
LID - 10.2353/jmoldx.2010.100021 [doi]
AB  - Because the activation of telomerase is a relatively early event in the 
      progression of cervical carcinogenesis, the expression of the human telomerase 
      RNA gene, TERC, has the potential to serve as a biomarker for both the diagnosis 
      and prognosis of cervical neoplasias. In total, 83 research centers participated 
      in the study, and 7786 patients were enrolled. TERC amplification was detected 
      using a dual-color fluorescence in situ hybridization (FISH) probe set, and these 
      results were compared with cytological and histological results, testing for 
      high-risk human papillomavirus (HPV) DNA (n = 2316 for the HPV DNA test), as well 
      as patient age. TERC amplification was found to be increased in more advanced 
      cases of cervical carcinogenesis. Moreover, a Youden's index value and the area 
      under the receiver operating characteristic (ROC) curve were also calculated for 
      samples with TERC amplification and found to be higher than the same values 
      calculated for both cytology and high-risk HPV analyses of the same samples. With 
      regard to cytological ASCUS and LSIL findings, the combination of HPV + TERC 
      testing showed the potential to provide effective triaging to detect CIN2(+). 
      Therefore, TERC amplification represents a valuable genetic biomarker, which in 
      combination with an evaluation of cytology or HPV testing, can achieve higher 
      sensitivity and specificity in distinguishing high-grade cervical lesions and 
      invasive cancers from low-grade lesions compared with conventional methods.
FAU - Jiang, Jing
AU  - Jiang J
AD  - Department of Obstetrics and Gynecology, Peking University People's Hospital, 
      Beijing 100044, China.
FAU - Wei, Li-Hui
AU  - Wei LH
FAU - Li, Ya-Li
AU  - Li YL
FAU - Wu, Rui-Fang
AU  - Wu RF
FAU - Xie, Xing
AU  - Xie X
FAU - Feng, You-Ji
AU  - Feng YJ
FAU - Zhang, Guo
AU  - Zhang G
FAU - Zhao, Chao
AU  - Zhao C
FAU - Zhao, Yun
AU  - Zhao Y
FAU - Chen, Zhong
AU  - Chen Z
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20100923
PL  - United States
TA  - J Mol Diagn
JT  - The Journal of molecular diagnostics : JMD
JID - 100893612
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cervix Uteri/cytology/pathology/physiology
MH  - China
MH  - *Epithelial Cells/cytology/pathology/physiology
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Middle Aged
MH  - RNA/*genetics
MH  - Sensitivity and Specificity
MH  - Telomerase/*genetics
MH  - *Uterine Cervical Neoplasms/diagnosis/genetics/pathology
MH  - Young Adult
MH  - *Uterine Cervical Dysplasia/diagnosis/genetics/pathology
PMC - PMC2963907
EDAT- 2010/09/25 06:00
MHDA- 2011/03/01 06:00
PMCR- 2011/11/01
CRDT- 2010/09/25 06:00
PHST- 2010/09/25 06:00 [entrez]
PHST- 2010/09/25 06:00 [pubmed]
PHST- 2011/03/01 06:00 [medline]
PHST- 2011/11/01 00:00 [pmc-release]
AID - S1525-1578(10)60131-6 [pii]
AID - JMDI60131 [pii]
AID - 10.2353/jmoldx.2010.100021 [doi]
PST - ppublish
SO  - J Mol Diagn. 2010 Nov;12(6):808-17. doi: 10.2353/jmoldx.2010.100021. Epub 2010 
      Sep 23.